UG Healthcare Corporation Limited: FY2025 Financial Analysis and Investor Insights
UG Healthcare Corporation Limited has released its audited financial statements for the year ended 30 June 2025, including a restatement of the previous year’s figures. This review provides a comprehensive breakdown of the Group’s financial performance, highlights material variances, and offers actionable recommendations for investors.
Key Financial Metrics Overview
Below is a summary of UG Healthcare’s most pertinent financial figures for FY2025 and FY2024, highlighting year-on-year changes as well as notable adjustments following the audit. There were no quarterly figures provided in the report, so the analysis focuses on annual comparisons.
| Metric |
FY2025 (Audited) |
FY2024 (Restated) |
YoY Change (%) |
| Revenue (S\$’000) |
144,074 |
115,205 |
+25.1% |
| Net Loss (S\$’000) |
(4,722) |
(6,684) |
-29.3% |
| EPS (Basic, cents) |
(0.66) |
(0.63) |
-4.8% |
| Total Comprehensive Loss (S\$’000) |
(5,264) |
(15,592) |
-66.2% |
| Total Equity (S\$’000) |
160,334 |
165,598 |
-3.2% |
Note: No dividends were disclosed in the financial report for FY2025 or FY2024. If dividends are relevant to investors, please consult future company announcements.
Historical Performance and Trends
- Revenue Growth: UG Healthcare achieved a strong revenue increase of 25.1% YoY, from S\$115.2 million in FY2024 to S\$144.1 million in FY2025.
- Net Loss Narrowed: The Group’s net loss decreased by 29.3%, indicating improved cost management and operational efficiency.
- EPS: Despite the improvement in net loss, EPS declined slightly, reflecting continued losses but a smaller magnitude.
- Total Comprehensive Loss: There was a significant reduction in total comprehensive loss, reflecting positive movements in foreign currency translation and operational results.
- Equity Position: The Group’s total equity declined by 3.2%, primarily due to continued losses and adjustments arising from acquisitions and restatements.
Exceptional Items, Restatements, and Audit Adjustments
- Material Audit Adjustments: The independent auditor proposed several adjustments, notably relating to the acquisition and consolidation of UG Healthcare (USA) Inc. and Unigloves GmbH. These included remeasurement gains, impairment of goodwill, and retrospective adjustments following purchase price allocations.
- Restatement of FY2024 Results: The previous year’s financials were restated to reflect the acquisition of Unigloves GmbH and related purchase price allocation, resulting in increased intangible assets and goodwill, as well as changes in deferred tax liabilities.
- Impairment Losses: The Group recognised an impairment loss on goodwill relating to UG Healthcare (USA) Inc., contributing to higher other expenses in FY2025.
- Gains on Remeasurement: There were notable gains on remeasurement of previously held interests and derivative financial assets, which impacted both FY2025 and FY2024 results.
Significant Corporate Actions and Events
- Acquisitions: The company completed acquisitions of Unigloves GmbH and UG Healthcare (USA) Inc., resulting in changes to the Group’s asset base, goodwill, and intangible assets.
- No Divestments, Fundraising, or Share Buybacks: The report did not mention any divestments, fundraising activities, share buybacks, or new mandates.
- No Disclosed Legal Disputes or Major Macroeconomic Events: There were no references to legal disputes, natural disasters, or significant policy changes affecting the business.
Cash Flow Analysis
- Operating Cash Flows: Net cash used in operating activities improved from S\$(8.6) million in FY2024 (restated) to S\$(2.9) million in FY2025, reflecting better working capital management and lower losses.
- Investing Activities: Net cash used in investing activities decreased sharply due to lower acquisition costs and higher net inflows from subsidiary acquisition.
- Financing Activities: Net cash generated from financing activities fell, primarily due to higher repayments of borrowings and reclassification of interest payments.
Chairman’s Statement
No Chairman’s Statement was included in the report.
Directors’ Remuneration
No information on directors’ remuneration was disclosed in this financial report.
Conclusion & Investor Recommendations
Overall Financial Performance: UG Healthcare Corporation Limited demonstrated significant revenue growth and managed to narrow its net loss in FY2025. The Group’s financial position remains robust, with a strong equity base, but persistent losses and asset impairments signal ongoing operational challenges. Material audit adjustments and restatements introduced additional transparency and reliability to the reported numbers.
Investor Recommendations
- If currently holding the stock: Investors may consider holding their position for now, given the improvements in revenue and narrowing losses. However, close monitoring is warranted due to continued net losses and the absence of dividend payments. Watch for future operational updates and management’s strategies to return to profitability.
- If not currently holding the stock: Caution is advised before initiating a new position, as the company has yet to demonstrate consistent profitability. Prospective investors should wait for further evidence of sustainable earnings and positive cash flow before committing capital.
Disclaimer: This analysis is based strictly on the information provided in the audited financial report for FY2025. It does not constitute financial advice. Investors should conduct their own due diligence or consult a professional adviser before making investment decisions.
View UGHealthcare Historical chart here
